AnteoTech Limited Overview
| Metric | FY2025 | FY2026 |
|---|---|---|
| Employee benefits expense incl. share-based payments (A$m) | 5.37 | 3.79 |
| Salaries and fees (A$m) | 4.31 | 2.95 |
| Superannuation (A$m) | 0.41 | 0.32 |
Headcount itself is not disclosed. The table below uses total employee benefits expense (A$m) as a proxy (source: Appendix 4E FY2026, Note 7).
AnteoTech is a Brisbane-based, pre-scale specialty chemicals and advanced-materials company. Its business is built on a single proprietary surface-chemistry platform based on metal-polymer coordination bonding ("nanoglue"). The company sells that platform into two very different markets:
Life Sciences (LS): in-vitro diagnostics, through the AnteoBind™ and AnteoBind™ NXT antibody-immobilisation reagents.
Advanced Battery Technologies (ABT): lithium-ion battery materials, through:
-
the Anteo X® silicon-anode cross-linker;
-
the Anteo S™ separator cross-linker;
-
the Anteo C current-collector primer;
-
the jointly developed SiMRAX product;
-
the Ultranode™ family of high-silicon anode formulations (Ultranode X, 70 and 95).
Revenue remains very small: A$0.47m in FY2026. It is concentrated in one customer, believed to be the Serum Institute of India under a five-year take-or-pay contract, which accounted for 59% of revenue.
The business is funded by equity raisings and Australian R&D tax incentives. After raising about A$13.8m in FY2026, it holds A$11.2m in cash and term deposits and has no bank debt.
Management describes the model as capital-light and partnership-driven, and calls FY2027 the "sales conversion" year. Investment value depends on converting technical validations into recurring commercial orders, in particular:
-
Ultranode 95 for drones and eVTOL;
-
CLIA diagnostics partnerships.
What the company does
AnteoTech develops and sells chemical reagents and material formulations based on its proprietary coordination-chemistry platform. The chemistry forms multiple metal-ligand bonds between a surface (polymer, metal, silica or silicon particle) and a target molecule or particle.
In diagnostics, this attaches antibodies and proteins to test surfaces with controlled orientation and stability. Examples of those surfaces are lateral-flow membranes, ELISA plates, CLIA magnetic beads and biosensors.
In batteries, the same chemistry acts as:
-
a cross-linker that holds silicon-rich anodes together through the large volume expansion of silicon during cycling;
-
a binder for ceramic coatings on separators;
-
an adhesion primer on current-collector foils.
The company's own description
The company describes itself in its ASX boilerplate (2026) as a supplier of chemicals and advanced material solutions to the lithium-ion battery and life-sciences markets. It says it uses its binding-chemistry platform technology to develop and commercialise solutions for a global customer base.
The FY2026 Appendix 4E (Note 4) states that the Group has one operating segment: "the development and commercialisation of AnteoTech's intellectual property and advanced chemicals and materials technologies". It adds that the ABT and LS businesses share common costs and that discrete financial information is not prepared for them.
Independent characterisation
| Era | Approximate period | Description |
|---|---|---|
| Diagnostics product company | 2015–2017 | Owned DIAsource ImmunoAssays (Belgium) |
| Platform-technology developer | 2018–2024 | Life sciences, COVID-19 rapid antigen test development, energy materials |
| Commercialisation-focused ingredient and formulation supplier | June 2025 onward | Strategic Review; emphasis on standardised, market-ready products sold through partners and distributors |
AnteoTech is best understood as an early-commercial, platform-IP company. Its revenue scale is that of a micro-cap ingredient supplier, but its cost base is that of an R&D organisation. FY2026 revenue from customers was A$467,589, against cash operating expenses of A$6.4–6.9m.
R&D tax incentive refunds of about A$2.4–2.6m a year fund roughly a third of the expense base. The rest has historically come from equity: shareholders have contributed A$116.8m in total, against accumulated losses of A$111.6m.
The company has moved through three strategic eras:
Business model and revenue model
| Revenue type | FY2025 (AUD) | FY2026 (AUD) | Share of FY2026 revenue (%) | Character |
|---|---|---|---|---|
| Product sales | 885,415 | 402,994 | 86.2 | Reagent and material sales: AnteoBind/NXT to diagnostics makers; ABT samples and early orders |
| Licence fees and royalties | 30,963 | 0 | 0.0 | Legacy licensing |
| Contract services | 52,500 | 64,595 | 13.8 | Paid development programmes, e.g. A$64,500 CLIA programme with a global life-sciences company |
| Total revenue from customers | 968,878 | 467,589 | 100.0 | — |
The revenue mix below is based on the revenue note in the Appendix 4E FY2026 (Note 5).
There is no subscription revenue. Licensing is now immaterial. The strategic intent, set out in the June 2025 Strategic Review, is to move away from bespoke R&D toward standardised product sales and joint-development agreements (JDAs) that lead to supply contracts.
Value-chain position
AnteoTech sits at the specialty-chemical / functional-additive tier. That is upstream of:
-
assay developers and diagnostics kit makers in Life Sciences;
-
electrode, separator and cell manufacturers in batteries.
It does not manufacture finished diagnostics or battery cells at commercial scale. For Ultranode, it supplies formulations and electrode samples and partners with cell makers and contract test centres such as the Battery Innovation Center in Indiana. Under the Airspeeder agreement (September 2026), it has stepped further downstream into cell design, but only at prototype scale and as consortium lead.
Customer types and end-markets
| Division | Customer types | End-markets | Geographic focus (FY2026 commentary) |
|---|---|---|---|
| Life Sciences | Vaccine makers (QC assays), IVD kit manufacturers, point-of-care developers, CLIA/ELISA platform companies, research institutes | In-vitro diagnostics (lateral flow, ELISA, CLIA, biosensors), vaccine quality control | India (Serum Institute of India), USA, Europe, Japan (Cosmo Bio), South Korea (KOMA) |
| Advanced Battery Technologies | Anode/electrode makers, separator makers, cell manufacturers, drone/UAS battery makers, eVTOL developers, consumer micro-battery makers | High-silicon anodes, ceramic-coated separators, current-collector coatings, drones/defence, eVTOL, 3C electronics, micro-mobility, medical micro-batteries | USA (Black Diamond Structures, two Ultranode 95 JDA negotiations, BIC), Europe (Wyon AG, Switzerland), South Korea (Xerabrid; battery distributor), Australia (Airspeeder) |
Strategy
Stated strategy
The Strategic Review outcomes (10 June 2025) set four pillars:
-
strategic direction and priorities;
-
cost reductions and continuous improvement;
-
strategic partnerships;
-
risk management and governance.
The resulting strategy has five recurring themes:
Accelerate revenue generation: through clearer value propositions and more commercial relationship management.
-
Shift from bespoke R&D to standardised, market-ready products.
-
Expand the opportunity pipeline in fast-growing markets: e-mobility, drones/defence and life sciences, across India, Europe and the USA.
Build partnerships: to scale globally in a capital-light way.
- Reduce costs, targeting net savings of A$1.6m a year.
The FY2026 webinar (30 Sep 2026) framed FY2027 as the "Sales Conversion" year, with a curated pipeline of qualified leads and samples under evaluation.
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| ARENA funding agreement | Oct 2024 | Up to A$4.0m for ABT development | First milestone extended to November 2026 |
| Queensland Critical Minerals & Battery Technology Fund | FY2025–FY2026 | Funding agreement | Company withdrew during FY2026 |
| Strategic Review and restructure | Jun 2025 | Cost-out, organisational redesign, commercial focus | Implemented. FY2026 cash opex A$6.86m vs A$8.45m in FY2025. |
| CRM and sales-system implementation | FY2026 | Structured lead tracking (leads → MQL → SQL → samples) | In place. Pipeline at 7 Sep 2026: LS 94 leads, 124 MQLs, 28 SQLs, 31 samples; ABT 22 leads, 51 MQLs, 29 SQLs, 32 samples. |
| Centralised global sales in Brisbane | 2,026 | Two sales and marketing personnel in Brisbane (Jan 2026) | Ongoing |
| BDS JDSA (SiMRAX) | Sep 2025 | US market entry for Anteo X plus carbon nanotubes | Six customers trialling |
| Ultranode 95 drone/defence programme | 2025–2026 | BIC third-party validation; two US JDAs | JDAs in negotiation; samples with two US drone battery makers |
| Wyon AG Ultranode 70 | Jun 2025 onward | Consumer and medical micro-battery evaluation | Ongoing |
| New product launches | FY2026 | Anteo S, Anteo C, SiMRAX ("three new offerings") | Customer evaluations |
| Xerabrid SCSA | Term sheet May 2026; binding Aug 2026 | Anteo S-enhanced separator solutions | Co-exhibiting at The Battery Show, Oct 2026 |
| Airspeeder consortium lead | Sep 2026 | eVTOL prototype cell design and supply | Cathode partner JDAs under negotiation |
| CLIA programme with global LS company | Apr–Jul 2026 | AnteoBind NXT in chemiluminescence immunoassays | Initial stage complete; advancing |
| Distribution expansion | 2025–2026 | Cosmo Bio (Japan LS); South Korea ABT distributor | Executed |
| Capital raising | Jan–Jun 2026 | A$3.81m placement; A$10.03m underwritten option exercise | Complete |
Medium-term targets and guidance
AnteoTech provides no quantitative revenue, EBITDA or profitability guidance. Qualitative FY2027 priorities are:
-
converting customer evaluations into sales in India, the US, Europe, Japan and South Korea;
-
progressing CLIA and ELISA partnerships;
-
executing Ultranode 95 JDAs;
-
maintaining financial discipline.
ESG commitments: No formal emissions targets have been disclosed.
Products & Services
Advanced Battery Technologies
| Product | Description | Key specifications / performance claims | Target customer | Launch / status | Pricing |
|---|---|---|---|---|---|
| Anteo X® | Water-based, binder-compatible cross-linker for high-silicon lithium-ion anodes. Improves cohesion and mechanical stability through silicon's volume expansion. | Improves cycle life and electrode integrity in silicon-containing anodes. Targets anodes with more than 15% silicon (BDS JDSA). | Anode/electrode makers, cell makers | Commercial; samples and early sales; multiple customer evaluations (2025–2026) | — |
| Anteo S™ | Cross-linker for ceramic-coated separators (CCS) | Improves ceramic coating adhesion and thermal/mechanical robustness. Being combined with Xerabrid separator designs. | Separator makers, cell makers | Launched FY2026. Seven OEMs requested samples after the Xerabrid binding SCSA (August 2026, per StockWire X). | — |
| Anteo C | Primer coating additive for current-collector foils (copper/aluminium) | Improves electrode-to-foil adhesion. A 20L sample was shipped for South Korean scale trials. | Electrode makers, foil makers | Launched and shipped for scale trials, June 2026; focus product at The Battery Show North America, October 2026 | — |
| SiMRAX | Joint product: Anteo X + Black Diamond Structures' MOLECULAR REBAR® single-walled carbon nanotube dispersion | More than 50% higher cycle life in high-silicon anode cells at ultra-low nanotube loadings. Six companies trialling it (Sep 2026). | US silicon-anode and cell makers | First customer samples Q3 FY2026 (Mar quarter 2026); in customer trials | — |
| Ultranode™ X | High-silicon anode formulation for long-cycle applications | 1,020 cycles at 80% capacity retention (announced Dec 2025) | Automotive EV, eVTOL | Development / validation | — |
| Ultranode™ 70 | About 70% silicon anode formulation | Balance of energy density and cycle life | 3C consumer electronics, micro-mobility, medical micro-batteries (Wyon AG) | Under evaluation by Wyon AG (Switzerland) in commercial cell format since mid-2025 | — |
| Ultranode™ 95 | 95% silicon anode formulation (integrated, "drop-in") | 1,800–2,400 mAh/g specific capacity (company). Independent BIC validation in a 5Ah multi-layer pouch: >390 Wh/kg cell specific energy; >300 cycles at 70% retention; about 40% energy-density uplift versus conventional cells (company claim). | Drone/UAS/defence battery makers; eVTOL (Airspeeder) | Validated May 2026. Two non-exclusive US JDAs in negotiation. Roll-to-roll coated electrode samples with two US drone battery makers. | — |
| Cell-design services | Next-generation cell chemistry design and prototype supply | Consortium lead role | Airspeeder (exclusive) | Supply agreement September 2026 | — |
Life Sciences
| Product | Description | Key specifications / performance claims | Target customer | Launch / status | Pricing |
|---|---|---|---|---|---|
| AnteoBind™ | Surface-activation reagent that binds antibodies and proteins to diagnostic surfaces through coordination chemistry | Improved sensitivity, reproducibility and orientation. Used by SII for vaccine quality-control assays. | Vaccine makers, IVD kit makers, lateral-flow developers | Mature commercial product. SII five-year take-or-pay contract from July 2024 (about US$1.8m over 5 years). | Contract-based; not publicly disclosed per unit |
| AnteoBind™ NXT | Next-generation version for ELISA, CLIA and biosensors | Up to 6× lower capture-antibody usage versus conventional methods. Antibodies can be up to 35% of assay cost (company claim). | CLIA/ELISA platform companies, IVD makers | Commercial. CLIA kit launch planned. Activated ELISA plate prototype under SII evaluation. | — |
| CLIA development programme | Collaborative product development with a large global life-sciences company (unnamed) | Initial stage completed 1 July 2026; A$64,500 programme value; A$61,595 recognised | Global IVD company | Advancing to next stage | Contract fee |
| Assay development / bioconjugation services | Contract services for assay developers | — | Point-of-care and diagnostics researchers | Ongoing | Fee-for-service |
Legacy and discontinued offerings
| Offering | Status |
|---|---|
| Mix&Go™ (original nanoglue diagnostics reagent brand) | Superseded by the AnteoBind branding |
| AnteoCoat™ (energy) and AnteoRelease™ (medical devices) | Earlier development programmes; not current commercial focus |
| DIAsource ELISA/RIA assay catalogue | Divested to BioVendor, 2017 |
| SARS-CoV-2 Rapid Antigen Test | Developed FY2021; no longer a reported revenue line |
Financial Detail
Division Overview
| Division | Contents | Products and services | Leadership |
|---|---|---|---|
Advanced Battery Technologies (ABT) | Anode, separator and current-collector chemistry; anode formulations; cell-design services | Anteo X®, Anteo S™, Anteo C, SiMRAX (with BDS), Ultranode™ X / 70 / 95 | Manuel Wieser, EGM – Advanced Battery Technology Business |
Life Sciences (LS) | Antibody/protein immobilisation reagents; assay development services | AnteoBind™, AnteoBind™ NXT (incl. activated ELISA plate prototype, CLIA kit in development), contract assay development | — |
Corporate | Finance, company secretarial, IR, sales operations (centralised in Brisbane from 2026) | — | Scott Waddell, CFO & Company Secretary |
“—” = not publicly disclosed.
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue from customers (AUD Mn) | 0.46 | 0.97 | 0.47 |
Total revenue and other income (AUD Mn) | 4.35 | 3.46 | 3.13 |
Loss before tax (AUD Mn) | -8.88 | -6.76 | -5.38 |
Revenue growth YoY (%) | 25.9 | 110.4 | -51.7 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Revenue by Segment
| Metric | FY2025 | FY2026 |
|---|---|---|
Product sales (AUD Mn) | 0.885 | 0.403 |
Licence fees and royalties (AUD Mn) | 0.031 | 0.000 |
Contract services (AUD Mn) | 0.053 | 0.065 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Revenue from largest single customer (% of external revenue) | 81.0 | 59.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from customers (AUD Mn) | 0.76 | 0.37 | 0.46 | 0.97 | 0.47 |
Revenue growth (%) | -15.3 | -51.9 | 25.9 | 110.4 | -51.7 |
R&D tax concession and other income (AUD Mn) | 1.51 | 3.22 | 3.78 | 2.43 | 2.60 |
Research expenses (AUD Mn) | 5.76 | 5.84 | 6.27 | 3.88 | 3.02 |
SG&A / administration and selling (AUD Mn) | 7.12 | 6.88 | 4.62 | 4.57 | 3.25 |
Asset write-down (AUD Mn) | 0.00 | 2.22 | 0.00 | 0.00 | 0.00 |
Depreciation and amortisation (AUD Mn) | 0.61 | 1.00 | 1.04 | 1.12 | 1.12 |
Share-based payments (AUD Mn) | 1.20 | 0.83 | 0.93 | 0.64 | 0.52 |
EBITDA, derived (AUD Mn) | -10.05 | -11.69 | -7.85 | -5.63 | -4.23 |
Loss before tax (AUD Mn) | -10.72 | -12.65 | -8.88 | -6.76 | -5.38 |
Net loss (AUD Mn) | -10.72 | -12.65 | -8.88 | -6.76 | -5.38 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansPer-Share Data and Share Count (m)
| Metric | FY2025 | FY2026 |
|---|---|---|
Basic EPS (A cents) | -0.26 | -0.19 |
Diluted EPS (A cents) | -0.26 | -0.19 |
Weighted average shares (m) | 2,613.6 | 2,842.1 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin (%) | -1,322 | -3,159 | -1,707 | -581 | -905 |
Net margin (%) | -1,411 | -3,419 | -1,930 | -698 | -1,150 |
Income Statement
| Metric | FY2025 | FY2026 |
|---|---|---|
Administration expenses (AUD Mn) | 3.85 | 2.56 |
Research expenses (AUD Mn) | 3.88 | 3.02 |
Selling and distribution (AUD Mn) | 0.64 | 0.70 |
Occupancy (AUD Mn) | 0.08 | 0.13 |
Depreciation (AUD Mn) | 1.12 | 1.12 |
Share-based payments (AUD Mn) | 0.64 | 0.52 |
Directors' fees (AUD Mn) | 0.335 | 0.208 |
Professional services (AUD Mn) | 0.67 | 0.34 |
Cash operating expenses excl. non-cash items, per company presentation (AUD Mn) | 8.45 | 6.86 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 10.10 | 2.72 | 5.03 | 2.34 | 5.70 |
Short-term term deposit (AUD Mn) | 0.00 | 0.00 | 0.00 | 0.00 | 5.50 |
Total current assets (AUD Mn) | 10.83 | 3.14 | 5.45 | 2.73 | 11.55 |
Total assets (AUD Mn) | 15.26 | 5.36 | 9.38 | 6.45 | 15.40 |
Lease liabilities, total (AUD Mn) | 1.04 | 1.31 | 2.31 | 1.94 | 2.13 |
Borrowings / asset finance (AUD Mn) | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 |
Total debt incl. leases (AUD Mn) | 1.03 | 1.31 | 2.33 | 1.96 | 2.15 |
Net cash incl. term deposit (AUD Mn) | 9.07 | 1.41 | 2.69 | 0.38 | 9.05 |
Total liabilities (AUD Mn) | 2.91 | 2.99 | 4.08 | 3.30 | 3.60 |
Shareholders' equity (AUD Mn) | 12.36 | 2.38 | 5.31 | 3.15 | 11.35 |
Goodwill and intangibles (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD Mn) | 9.21 | 1.34 | 3.66 | 1.42 | 10.12 |
Contributed equity (AUD Mn) | 87.45 | 89.30 | 99.82 | 103.78 | 116.83 |
Accumulated losses (AUD Mn) | -78.36 | -91.02 | -99.90 | -106.66 | -112.03 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -8.69 | -8.08 | -6.52 | -5.83 | -3.53 |
Capital expenditure (AUD Mn) | -3.12 | -0.69 | -1.06 | -0.22 | -0.05 |
Free cash flow (AUD Mn) | -11.81 | -8.77 | -7.58 | -6.05 | -3.58 |
Gross equity issued (AUD Mn) | 0.76 | 1.85 | 11.48 | 4.31 | 13.84 |
Lease principal repaid (AUD Mn) | -0.24 | -0.46 | -0.66 | -0.64 | -0.60 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE on average equity (%) | -172 | -231 | -160 | -74 |
ROA on average assets (%) | -123 | -120 | -85 | -49 |
Current ratio (x) | 1.74 | 3.04 | 2.08 | 8.08 |
Debt / equity incl. leases (x) | 0.55 | 0.44 | 0.62 | 0.19 |
Asset turnover (x) | 0.04 | 0.06 | 0.12 | 0.04 |
Business Lines
| Line | Peak | FY2026 | Change |
|---|---|---|---|
Net loss | A$12.65m (FY2023, incl. A$2.22m write-down) | A$5.38m | -57% |
Cash operating expenses | A$10.89m (FY2024) | A$6.86m | -37% |
Free cash outflow | A$11.81m (FY2022) | A$3.58m | -70% |
Region / Country Details
| Region / country | Evidence of revenue activity (FY2025–FY2026) | Indicative significance |
|---|---|---|
India | Serum Institute of India five-year take-or-pay AnteoBind contract; largest customer was 81% (FY2025) and 59% (FY2026) of revenue | Very likely the largest revenue country (inferred, not disclosed) |
Europe | CLIA development programme with a global life-sciences company (A$61,595 recognised FY2026); Wyon AG (Switzerland) Ultranode 70 evaluation | Contract-services revenue; Europe-based programme per webinar |
USA | BDS JDSA/SiMRAX trials; BIC validation programme; two Ultranode 95 JDA negotiations; LS targets in POC, CLIA and ELISA | Pipeline; revenue not yet material |
South Korea | KOMA (LS distributor since 2015); Xerabrid binding SCSA (Aug 2026); ABT distributor (Aug 2025); Anteo C trials | Pipeline / samples |
Japan | Cosmo Bio appointed LS distributor (28 May 2026) | New channel; no revenue disclosed |
Australia | Airspeeder supply agreement (Sep 2026); ARENA funding (grant, not revenue) | Prototype supply; immaterial revenue to date |
Valuation Snapshot
| Metric | Value | Source / date |
|---|---|---|
Recent price | A$0.016 | InvestSMART / MarketScreener, about 25–28 Sep 2026 |
52-week range | A$0.010 – A$0.049 | Stocklight (mid-2026) |
1-year performance | About -33% (A$0.024 on 3 Oct 2025 to about A$0.016) | StockAnalysis.com; analyst calculation |
5-year average annual change | About -17.4% a year | Pearler (June 2026) |
Notable single-day move | +30.8% on 21 May 2026 (Ultranode 95 validation) | Stocklight |
Market Valuation
| Metric | Jun 2026 | Aug 2026 | Sep 2026 |
|---|---|---|---|
Market capitalisation (AUD Mn) | 88 | 59 | 56 |
Valuation Multiples
| Multiple | AnteoTech | Comment |
|---|---|---|
Market cap (AUD Mn) | About 52 | Company cited A$56m at 23 Sep 2026 |
Enterprise value (AUD Mn) | About 43 | Market cap 52 – cash and deposit 11.2 + leases and debt 2.15 |
EV/Sales (FY2026) | About 92x | A$43m / A$0.47m |
P/B | About 4.6x | A$52m / A$11.35m equity |
Balance Sheet and Share Count (m)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross equity raised (AUD Mn) | 0.76 | 1.85 | 11.48 | 4.31 | 13.84 |
Shares on issue at year end (m) | 1,988 | 2,050 | 2,468 | 2,705 | 3,260 |
Capital Markets
| Item | Within 12 months | Beyond 12 months | Notes |
|---|---|---|---|
Asset finance | A$5,209 | A$9,250 | — |
Lease liabilities | A$558,353 | A$1,574,609 | Brandl Street lease runs to 30 Nov 2029 |
Analyst Conclusions
Management guidance
No numerical guidance is given. Management's qualitative guidance (FY2026 webinar, 30 Sep 2026; Appendix 4E going-concern note) covers:
FY2027 as the "Sales Conversion" year: Convert 57 sales-qualified leads and 63 samples under evaluation into orders.
ABT: progress two Ultranode 95 drone JDAs in the US, Wyon's Ultranode 70 evaluation, SiMRAX customer trials, Anteo S/C/X conversion, and the Airspeeder consortium.
Life Sciences: progress CLIA and ELISA partnerships and expand with SII.
Financial discipline: continued cost control.
R&D refund: about A$1.9m to be booked in FY2027.
Consensus growth expectations: Not publicly disclosed.
Bull case
-
Validated product meets an urgent market. Ultranode 95's independent BIC data (>390 Wh/kg in a commercial 5Ah cell) suits drone and defence buyers that value energy density over cycle life. Signed US JDAs could turn into supply volumes quickly. Amprius's 202% revenue growth to US$73m in CY2025 shows how fast this niche can scale.
-
Several shots on goal with funded runway. A$11.2m in cash and deposits, an annual burn of about A$4–5m after R&D refunds, and roughly 7–8 commercial programmes (BDS/SiMRAX, Xerabrid/Anteo S, Wyon, Airspeeder, two Ultranode 95 JDAs, the CLIA partner, SII expansion). A single conversion could re-rate a A$50m-scale company.
-
Operating leverage. With cash opex down 37% in two years to A$6.86m, incremental high-margin chemical sales flow largely to the bottom line. Life Sciences carries a credible cost-saving proposition (up to 6× less antibody) in a US$56bn IVD market.
Bear case
-
History of non-conversion. After more than 25 years as a listed company and about A$117m of contributed equity, customer revenue is still below A$1m. FY2026 revenue fell 52%. JDAs "under negotiation" since early FY2026 remain unsigned.
-
Concentration and fragility. 59% of revenue comes from one customer. The restatement after the preliminary results, the CFO turnover and a three-person board signal limited institutional infrastructure. Going-concern uncertainty persists.
-
Competition and dilution. Silicon-anode competitors have balance sheets one to two orders of magnitude larger (Enovix about US$621m). Further raises at depressed prices remain likely before cash-flow breakeven: shares on issue are up 64% since FY2022, with 298m options outstanding.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| 12–15 Oct 2026 | The Battery Show North America (Anteo S presentation, Xerabrid booth, SiMRAX customer meetings) |
| Oct 2026 | Q1 FY2027 Appendix 4C: customer receipts (incl. the A$134k SII shipment), cash burn |
| Nov 2026 | ARENA first-milestone deadline; AGM (remuneration votes, option packages) |
| 16–19 Nov 2026 | MEDICA Düsseldorf (Life Sciences) |
| Nov 2026 onward | Airspeeder international race series; prototype cell progress |
| 18 Dec 2026 | A$5.5m term deposit matures |
| FY2027 (any time) | Execution of Ultranode 95 JDAs; SiMRAX purchase orders; CLIA stage-2 / supply agreement; Wyon commercial decision |
| Feb 2027 | H1 FY2027 results (revenue trajectory; receipt of the R&D refund of about A$1.9m) |
| Ongoing | Pipeline metrics (SQLs → orders); new capital raisings; options exercised or lapsed |
Analyst verdict
AnteoTech goes into FY2027 in a better financial position than at any time since FY2022. It has A$11.2m of cash and term deposits, negligible financial debt, and a cost base cut by more than a third in two years. Its core claims also now carry more credible external validation. The most material is the Battery Innovation Center's confirmation of Ultranode 95 performance in a commercial-format cell. The company has added three new battery products (Anteo S, Anteo C and SiMRAX) and binding partner agreements with Black Diamond Structures, Xerabrid and Airspeeder. With a structured sales pipeline of 57 qualified leads and 63 samples in evaluation, it has more simultaneous commercial options than at any point in its recent history.
The investment case, however, is still a commercialisation bet, not a business that can be valued on earnings. Customer revenue of A$0.47m in FY2026 covers under 7% of cash operating costs. More than half of it comes from one Indian customer under a contract worth about US$0.36m a year. The JDAs that would change the revenue profile remain unsigned after roughly a year of negotiation.
The restatement of the FY2026 loss after the preliminary results was non-cash and modest. Even so, together with a three-member board, a recently rebuilt finance function and continuing going-concern language, it argues for a governance discount. At an enterprise value of about A$43m (roughly 90x trailing sales), the market is already paying for partial conversion of the pipeline.
On balance, AnteoTech is a speculative, catalyst-driven holding. The single most important monitorable is the signing of at least one Ultranode 95 JDA, or a SiMRAX or CLIA supply contract with defined volumes, before mid-2027. Absent that, the cash runway will be spent on validation rather than revenue, and the next capital raising will set the valuation. With it, the company's reduced cost base gives meaningful operating leverage. The sensible stance today is neutral-to-speculative: technical and financial de-risking has clearly improved, but commercial proof is still outstanding.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background | Age |
|---|---|---|---|---|
Ms Glenda McLoughlin | Non-Executive Chair | Chair since 1 Apr 2025; director before that (appointment date not confirmed) | More than 20 years on listed company boards. Experience across energy, medical diagnostics, telecommunications, IT, media, transport and financial services. | — |
Dr Geoffrey Cumming | Non-Executive Director | Joined 2009 as CEO; retired as CEO in 2016; now NED | Led Anteo from 2009, including the DIAsource acquisition and the associated fundraising. Co-chaired the Remuneration/Nomination Committee from April 2025. | — |
Ms Merrill Gray | Managing Director & CEO | NED from January 2025 (sources differ: 15 Jan vs 31 Jan 2025); Interim MD/CEO from 16 Apr 2025; permanent MD/CEO from 19 Aug 2025 | B.Sc, B.Min.Tech, MBA, MAusIMM, AFAIM. More than 30 years in mineral processing, the energy transition, and critical-minerals and battery-materials supply chains. Former ASX-listed MD/CEO. | 60 (Simply Wall St) |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | Tenure / notes |
|---|---|---|
Merrill Gray | MD & CEO | See above |
Scott Waddell | Chief Financial Officer & Company Secretary | Interim CFO & CoSec from 2 Feb 2026; permanent appointment announced 17 Jul 2026 |
Manuel Wieser | Executive General Manager – Advanced Battery Technology Business | Presenting at The Battery Show North America, Oct 2026 |
Directors' Remuneration
| Metric | FY2025 | FY2026 |
|---|---|---|
Total directors' fees (AUD Mn) | 0.335 | 0.208 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Apr 2025 | Glenda McLoughlin appointed Chair; two directors (incl. Katherine Woodthorpe AO) retire | Board renewal and cost reduction |
16 Apr 2025 | David Radford (CEO since Oct 2022) steps down; Merrill Gray Interim MD/CEO | Shift from R&D to commercialisation |
1 May 2025 | Director departure announced | Board downsizing |
19 Aug 2025 | Merrill Gray appointed permanent MD/CEO | Strategic Review execution |
9 Jan 2026 | CFO Andrew Cook resigns | — |
2 Feb 2026 | Scott Waddell Interim CFO & Company Secretary | — |
17 Jul 2026 | Scott Waddell confirmed as CFO & Company Secretary | — |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | Marcolongo Nominees Pty Ltd | 99,024,869 | 3.04 |
| 2 | First Cape Management Pty Ltd | 55,195,509 | 1.69 |
| 3 | Citicorp Nominees Pty Limited | 52,095,735 | 1.60 |
| 4 | AWO & CAO Investments Pty Ltd | 48,900,000 | 1.50 |
| 5 | Addison Lake Quality Hire Pty Limited | 38,844,879 | 1.19 |
| 6 | Mr Peter Frederick Kemmis | 36,216,676 | 1.11 |
| 7 | BNP Paribas Nominees Pty Ltd | 34,418,226 | 1.06 |
| 8 | Fossil Super Pty Ltd | 33,920,000 | 1.04 |
| 9 | Mr Claus Kurt Dzalakowski | 30,000,000 | 0.92 |
| 10 | Bond Street Custodians Limited | 25,100,000 | 0.77 |
Competitive Landscape
Competitors by Segment
| Area | Competitor | Type | Relative positioning vs AnteoTech |
|---|---|---|---|
Silicon anode (cells and materials) | Amprius Technologies (NYSE: AMPX) | Silicon-anode cell maker | Far larger. FY2025 revenue US$73.0m. Direct competitor in drone/UAS high-energy cells; also a potential customer archetype. |
Silicon anode cells | Enovix (Nasdaq: ENVX) | 3D silicon-anode cell maker | FY2025 revenue US$31.8m; R&D US$110.3m; about US$621m in cash and securities. Competes in defence and consumer segments. |
Silicon anode materials | Group14 Technologies | Silicon-carbon composite supplier (private) | Scale materials supplier; financials not publicly disclosed |
Silicon anode materials | Sila Nanotechnologies | Silicon anode material supplier (private) | Scale supplier; financials not publicly disclosed |
Silicon anode materials | Nexeon (UK) | Silicon anode materials (private) | Financials not publicly disclosed |
Silicon anode materials | NEO Battery Materials (TSXV: NBM) | Silicon anode developer | — |
Anode materials (ASX peers) | Altech Batteries (ASX: ATC), Talga Group (ASX: TLG), Novonix (ASX: NVX) | ASX-listed anode-material developers | — |
Binders / cross-linkers / CNT | Arkema, Syensqo (ex-Solvay), Zeon, Ashland (binders); OCSiAl (TUBALL SWCNT) | Large specialty chemical makers | Incumbent suppliers with scale; AnteoTech positions as a complementary additive |
Diagnostics surface chemistry / conjugation | Thermo Fisher (Pierce), Merck KGaA/MilliporeSigma, Cytiva, Abcam (Lightning-Link), Bio-Techne | Global life-science tools makers | Dominant incumbents in conjugation and coupling reagents; AnteoTech competes on performance and antibody savings |
Peer Comparison FY2025
| Metric | FY2024 | FY2025 |
|---|---|---|
AnteoTech revenue (AUD Mn, FY to June) | 0.46 | 0.97 |
Amprius revenue (USD Mn, CY) | 24.2 | 73.0 |
Enovix revenue (USD Mn, CY) | 23.1 | 31.8 |
Peer Comparison FY2026
| Company | Latest FY revenue growth (%) | R&D intensity (%) | Cash / liquidity |
|---|---|---|---|
AnteoTech (FY2026) | -51.7 | 647 (A$3.02m R&D / A$0.47m revenue) | A$11.2m cash plus term deposit |
Amprius (CY2025) | 202 | 12.9 (US$9.4m / US$73.0m) | US$91.9m cash |
Enovix (CY2025) | 38 | 347 (US$110.3m / US$31.8m) | About US$621m cash and securities |
Recent Developments
--



